Evidence map›Paper›PMID 42910401›Full record

ArticleOpen forum infectious diseases2026

Etiology and Outcomes of Bloodstream Infections by Immunosuppression Type: A Population-Based Laboratory Surveillance Study.

Oskar Ljungquist, Fredrik Resman, Karl Oldberg, Anna Bläckberg, Torgny Sunnerhagen, Gustav Torisson

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oskar LjungquistDivision of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0003-2951-1309
Fredrik ResmanClinical Infection Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden.ORCID https://orcid.org/0000-0002-3433-512X
Karl OldbergDivision of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.ORCID https://orcid.org/0009-0008-7446-463X
Anna BläckbergDivision of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0003-2778-5314
Torgny SunnerhagenDivision of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0002-9240-2378
Gustav TorissonClinical Infection Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden.ORCID https://orcid.org/0000-0001-9012-2068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An increasing proportion of the population receives immunosuppressive treatment. There is a lack of guidelines for bloodstream infections (BSIs) in this group. This study aims to provide a comprehensive analysis of the etiology and outcomes in BSI associated with underlying immunosuppression. Methods: This population-based laboratory surveillance study included all positive blood cultures in southern Sweden, from 2013 through 2023. Immunosuppression was defined using diagnostic codes, medications, and laboratory data. We defined 6 categories of immunosuppression: antineoplastic treatment, neutropenia, immunosuppressant medication, organ transplants, primary immunodeficiency, and human immunodeficiency virus infection. Results: In total, 8058 of 47 552 (16.9%) BSI episodes were associated with underlying immunosuppression. This proportion increased over time (rate ratio, 1.019 per year [95% confidence interval {CI}, 1.012-1.027], Conclusions: This study provides an updated summary of etiology and outcomes in BSI associated with immunosuppression. Underlying immunosuppression is increasingly prevalent among patients with BSI and is associated with resistance to cephalosporins and increased short-term mortality. Clinical guidelines for the management of BSI in immunosuppressed patients are warranted.

Indexed as

antibioticsbloodstream infectionsimmunosuppressionmortality

Identifiers

PMID42910401
PMCPMC13686795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.